ConductScience.org, home

Comparison · NCT01864746-deaths

Palbociclib vs Placebo: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Palbociclib vs Placebo: deaths from any cause. Trial comparisons, record NCT01864746-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01864746-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.09950.07860.125wilson
Risk in group 20.110.08730.137wilson
Risk difference, group 1 minus group 2-0.0101-0.04450.024newcombe hybrid score
Risk ratio, group 1 over group 20.9080.6551.26log
Odds ratio, group 1 over group 20.8970.6241.29log
Number needed to treat, for one fewer death from any cause on Palbociclib than on Placebo98.7from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Palbociclib
Palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles~Palbociclib PD-0332991: palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
63633EG000
Group 2Placebo
Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a28-day cycle for thirteen cycles~Placebo: Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
67611EG001

Harm

What it counts
Total, all-cause mortality
Time frame
For AEs and SAEs, the reporting period is from the time the patient took the first dose of the investigational product until (and including) 30 calendar days after the last administration of the investigational product (i.e., from first dose to 30 days after last dose). Serious and Other (Not Including Serious) Adverse Events were assessed for up to 14 months, and all-cause mortality was assessed up to 6 years and 6 months.

Source ClinicalTrials.gov

Trial

Title
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
NCT number
NCT01864746
Phases
PHASE3
Conditions
Breast Cancer, Hormonreceptor Positive, Her2-normal, Postneoadjuvant Treatment With CDK 4/6 Inhibitor, CPS-EG Score
Interventions
Palbociclib PD-0332991, Placebo
Lead sponsor
GBG Forschungs GmbH
Results first posted
2023-12-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01864746-deaths